Navigation Links
Interleukin Genetics Announces Strategic Divestment of Alan James Group
Date:7/2/2009

WALTHAM, Mass., July 2 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that on June 30, 2009 it executed an agreement to sell the Alan James Group assets of its subsidiary AJG Brands, Inc. to Pep Products, Inc., a subsidiary of Nutraceutical Corporation, for approximately $4.6 million in cash. The transaction was completed following the close of business on June 30th.

"While the Alan James Group business saw an increase in sales during the last fiscal year and we were able to introduce two new products to the market in the past seven months, this transaction allows us to focus our efforts on growing our core genetic testing business. The sale of AJG provides non-dilutive cash to continue development and promotion of our genetic testing services and products including our new brand of Inherent Health tests," said Lewis H. Bender, CEO, Interleukin Genetics.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI) develops and markets genetic tests, including its new brand of Inherent Health genetic test products that empower consumers to maintain health and wellness, and assists pharmaceutical companies in the development and marketing of targeted therapeutics. The Company leverages its research, intellectual property, and biomarker development experience to facilitate the emerging personalized health market. Interleukin Genetics is headquartered in Waltham, MA. For more information please visit www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding the Company's ability to develop genetic tests that identify genetic variations that affect risk of heart disease, periodontal disease and osteoporosis, nutritional needs and optimal weight-loss methods, to identify nutritional and lifestyle decisions that favorably affect such conditions, to provide such information in a format tailored to the individual, and to otherwise make progress in advancing the Company's core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of the Company's products, the risk of technology and product obsolescence, delays in product development, the performance of commercial partners, the availability of adequate capital, the actions of competitors and other competitive risks, and those other risks and uncertainties described in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Interleukin Genetics Launches Inherent Health Brand of Genetic Tests Offering Clear and Personalized Insights to Wellness
2. Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting
3. Interleukin Genetics Reports First Quarter 2009 Financial Results
4. NYSE Amex Accepts Interleukin Genetics Plan to Meet Continued Listing Standards
5. Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention
6. Interleukin Genetics Announces Conference Call to Discuss First Quarter 2009 Results
7. Interleukin Genetics Grants LABEC Pharma a License for Sales and Distribution of Its Heart Health Genetic Test
8. Interleukin Genetics Receives NYSE Amex Staff Determination, Requests Oral Hearing Before the Listing Qualifications Panel
9. Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter 2008 Results
10. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
11. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... The American Society for ... (PA) form for prescribers to improve patients’ access to the revolutionary therapy for ... as part of the article entitled “PCSK9 Inhibitor Access Barriers: Issues and ...
(Date:3/22/2017)... Georgia (PRWEB) , ... March 22, 2017 , ... ... time consuming and frustrating and this tool bypasses that. Healthcare facilities across ... identified an opportunity to offer their clients and hospitals, across the country, an ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... the nation’s leading digital and print media enterprise focused on cancer patients, cancer ... content, has released a special 12-part educational video series, “No Ifs, Ands, or ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... solution provider, today announced that its digital marketing solutions have enabled Children’s Hospital ... investment in 24 months. , Recognizing the value of a digital marketing ...
(Date:3/22/2017)... ... 2017 , ... An intensive search of the medical literature has revealed no ... PhD. He says investigating this possibility, is important because Miami-Dade in 2016 ... infections with HIV. , His findings appear on Analizir.com. . Dr. ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 22, 2017  Levine Cancer Institute ... (CT) unit designed to address lung cancer diagnosis, ... the Carolinas. The mobile lung unit is the ... education and treatment interventions through integrated mobile technology, ... Financial barriers and a lack of public ...
(Date:3/22/2017)... 2017 MarketNewsUpdates.com News Commentary  ... ... CBD oil continues to rise in popularity with consumers, ... are enhancing production through acquiring innovative assets and other ... sector include: Future Farm Technologies Inc (OTC: FFRMF) (CSE: FFT.CN), ...
(Date:3/22/2017)... , March 22, 2017  Varex Imaging Corporation ... entered into a renewed three-year pricing agreement with Toshiba ... supply its computed tomography (CT) tubes for integration into ... This renewed agreement will be effective April 1, 2017. ... this renewed agreement are estimated to be in the ...
Breaking Medicine Technology: